KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Sarepta Therapeutics (SRPT) Enterprise Value (2016 - 2025)

Sarepta Therapeutics has reported Enterprise Value over the past 15 years, most recently at -$939.6 million for Q4 2025.

  • Quarterly results put Enterprise Value at -$939.6 million for Q4 2025, up 14.26% from a year ago — trailing twelve months through Dec 2025 was -$939.6 million (up 14.26% YoY), and the annual figure for FY2025 was -$939.6 million, up 14.26%.
  • Enterprise Value for Q4 2025 was -$939.6 million at Sarepta Therapeutics, down from -$851.0 million in the prior quarter.
  • Over the last five years, Enterprise Value for SRPT hit a ceiling of -$242.5 million in Q3 2024 and a floor of -$2.1 billion in Q4 2021.
  • Median Enterprise Value over the past 5 years was -$1.7 billion (2021), compared with a mean of -$1.5 billion.
  • Biggest five-year swings in Enterprise Value: skyrocketed 86.01% in 2024 and later plummeted 250.97% in 2025.
  • Sarepta Therapeutics' Enterprise Value stood at -$2.1 billion in 2021, then grew by 5.98% to -$2.0 billion in 2022, then increased by 15.74% to -$1.7 billion in 2023, then skyrocketed by 34.62% to -$1.1 billion in 2024, then grew by 14.26% to -$939.6 million in 2025.
  • The last three reported values for Enterprise Value were -$939.6 million (Q4 2025), -$851.0 million (Q3 2025), and -$800.1 million (Q2 2025) per Business Quant data.